Fibroblast Growth Factor (FGF) signaling represents one of the most evolutionarily conserved and biologically important pathways in nervous system development, maintenance, and disease. The FGF family comprises 22 growth factors in humans that signal through four receptor tyrosine kinases (FGFR1-4), playing critical roles in neurogenesis, synaptic plasticity, neuronal survival, and Response to injury. Dysregulation of FGF signaling contributes to the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and multiple sclerosis (MS).
The FGF family encompasses a diverse group of polypeptides involved in multiple biological processes. In the nervous system, FGFs are essential for:
- Neural development: Patterning, proliferation, and differentiation of neural progenitor cells
- Neurogenesis: Continuous generation of new neurons in adult brain niches
- Synaptic plasticity: Formation and maintenance of synaptic connections
- Neuronal survival: Protection against various apoptotic stimuli
- Response to injury: Promotes repair and regeneration following neural injury
FGF signaling involves multiple downstream pathways including:
- RAS/MAPK/ERK: Primary mitogenic pathway
- PI3K/Akt: Cell survival and metabolic regulation
- PLCγ: Calcium signaling and protein kinase C activation
- STAT pathways: Gene expression regulation
- JNK/p38: Stress response and apoptosis
The canonical FGFs (FGF1-10, FGF16-18, FGF20) require heparin/heparan sulfate for receptor binding:
| FGF |
Primary CNS Expression |
Key Functions |
Disease Relevance |
| FGF1 (aFGF) |
Widely distributed |
Neuroprotection, angiogenesis |
Reduced in AD |
| FGF2 (bFGF) |
Hippocampus, SVZ |
Neurogenesis, synaptic plasticity |
Neuroprotective in PD |
| FGF4 |
Neural progenitors |
Stem cell proliferation |
Therapeutic potential |
| FGF5 |
Cortex, hippocampus |
Neuronal differentiation |
Altered in HD |
| FGF8 |
Midbrain, substantia nigra |
Dopaminergic development |
PD therapeutic target |
| FGF9 |
Astrocytes, glia |
Neuronal survival, gliogenesis |
Neuroprotective |
| FGF13 (FGF12) |
Cortex, hippocampus |
Calcium regulation |
Impaired in HD |
| FGF14 (FGF14) |
Hippocampus, cortex |
Synaptic function |
AD vulnerability factor |
| FGF17 |
Cortex, striatum |
Cognitive function |
Downregulated in AD |
| FGF18 |
Hippocampus |
Oligodendrocyte differentiation |
MS therapeutic target |
| FGF20 |
Substantia nigra |
Dopaminergic survival |
PD therapeutic target |
| FGF21 |
Widely expressed |
Metabolic regulation |
PD autophagy link |
| FGF22 |
Hippocampus |
Synaptic formation |
AD neuroprotection |
| FGF23 |
Choroid plexus |
Klotho interactions |
Cognitive decline |
The endocrine FGFs (FGF19, FGF21, FGF23) have low heparin affinity and act as hormones:
- FGF19 (FGF15 in mice): Expressed in intestine, regulates metabolism
- FGF21: Highly expressed in liver, cross-talk with brain; implicated in PD autophagy
- FGF23: Produced in bone, signals to brain via Klotho
FGFRs (FGFR1-4) are transmembrane receptor tyrosine kinases with characteristic architecture:
- Extracellular domain: Comprises 3 immunoglobulin-like domains (D1-D3)
- Transmembrane helix: Single pass membrane-spanning region
- Tyrosine kinase domain: Intracellular catalytic domain
Isoform diversity: Alternative splicing generates multiple receptor isoforms:
- FGFR1: Expressed in neural stem cells, astrocytes
- FGFR2: Expressed in glial progenitors, ependymal cells
- FGFR3: Expressed in mature neurons
- FGFR4: Limited CNS expression, more peripheral
flowchart TD
A["FGF Ligand"] --> B["Heparan Sulfate"]
B --> C["FGF-FGFR Complex"]
C --> D[" Receptor Dimerization"]
D --> E["Autophosphorylation"]
E --> F["Tyrosine Kinase Activation"]
F --> G["RAS/MAPK Pathway"]
F --> H["PI3K/Akt Pathway"]
F --> I["PLCγ Pathway"]
F --> J["STAT Pathway"]
G --> K["Cell Proliferation"]
G --> L["Differentiation"]
H --> M["Cell Survival"]
H --> N["Metabolism"]
I --> O["Calcium Signaling"]
I --> P["PKC Activation"]
J --> Q["Gene Expression"]
K --> R["Neuroprotection"]
L --> R
M --> R
N --> R
O --> R
P --> R
Q --> R
- FRS2α/β (Fibroblast growth factor receptor substrate 2): Primary docking protein
- GRB2: Links to RAS/MAPK pathway
- PLCγ1: Calcium signaling
- STAT3: Gene expression regulation
The MAPK cascade is the primary mitogenic pathway activated by FGFRs:
- RAS activation: SOS (Son of Sevenless) recruited via FRS2α
- RAF activation: MAPKKK step
- MEK1/2: MAPKK activation
- ERK1/2: MAPK activation and nuclear translocation
- Transcription factors: Elk-1, CREB, c-Fos, c-Myc
Downstream effects:
- Cell proliferation and cycle progression
- Neuronal differentiation
- Synaptic plasticity
- Long-term potentiation (LTP)
The PI3K/Akt pathway mediates survival and metabolic effects:
- PI3K activation: Via GAB1 or direct recruitment
- PIP3 production: Phosphatidylinositol-3,4,5-trisphosphate
- Akt activation: PDK1 (Thr308) and mTORC2 (Ser473) phosphorylation
- Downstream targets: mTOR, FOXO, BAD, caspase-9
Cell survival mechanisms:
- Phosphorylation and inhibition of pro-apoptotic proteins
- Autophagy regulation
- Protein synthesis via mTORC1
- Metabolic regulation
Phospholipase C gamma produces second messengers:
- PLCγ activation: Phosphorylated by FGFR
- PIP2 hydrolysis: Phosphatidylinositol-4,5-bisphosphate
- DAG production: Diacylglycerol → PKC activation
- IP3 production: Inositol trisphosphate → calcium release
Physiological effects:
- Calcium-dependent synaptic plasticity
- Neurotransmitter release
- Gene expression via CaMK pathways
- Depolarization-dependent signaling
Stress-activated MAP kinases:
- JNK (c-Jun N-terminal kinase): Pro-apoptotic signaling
- p38:Inflammatory responses, cytokine production
- Cross-talk with other survival pathways
FGF signaling is profoundly altered in AD:
- Expression: Reduced in AD hippocampus and cortex [@bfgf cns]
- Therapeutic potential: Improves memory in AD mouse models [@fgf2memory]
- Mechanism: Promotes hippocampal neurogenesis, synaptic plasticity
- Autophagy: Induces autophagy via AMPK to reduce Aβ burden [@fgf2autophagy]
- Novel findings: Ferroptosis suppression via YAP pathway
- Cognitive protection: Maintains cognitive function
- Therapeutic targeting: FGFR2 agonists in development
- Synaptic regulation: Critically regulates synaptic function
- AD impairment: Lost in AD brain, contributes to synaptic dysfunction [@fgf14synapse]
- Cognitive function: Promotes cognitive function
- AD downregulation: Significantly decreased in AD [@fgf17cognition]
- Intranasal FGF2 delivery: Phase 2 clinical trials
- AAV-FGF2: Gene therapy approaches
- FGFR agonists: Small molecule development
FGF signaling provides dopaminergic neuron protection:
- Specificity: Highly specific for dopaminergic neurons
- Neuroprotection: Protects substantia nigra pars compacta neurons
- Clinical trials: Phase 1/2 gene therapy trials ongoing
- Dopaminergic protection: Protects SNc neurons
- Mechanism: Through PI3K/Akt and MAPK pathways
- Development: Critical for dopaminergic neuron development
- Therapeutic potential: Replacement therapy target [@fgf8dopamine]
- Mitochondrial protection: Against mitochondrial toxins [@fgf9neuroprotection]
- Autophagy regulation: Complex interplay with PD pathology
- Metabolic effects: Improves neuronal metabolism
FGF signaling in motor neuron disease:
- FGF2: Promotes motor neuron survival
- FGFR1: Expressed on motor neurons
- Therapeutic challenge: Delivery across blood-brain barrier
FGF alterations in HD:
- Striatal protection: Suppresses striatal cell death via ERK
- Mechanism: ERK signaling pathway
- Calcium dysregulation: Implicated in HD pathophysiology [@fgf13calcium]
- Therapeutic target: Stabilizes calcium homeostasis
- Altered expression: Changes in HD striatum
FGF in demyelination and repair:
- FGF2: Promotes oligodendrocyte progenitor proliferation
- FGF18: Enhances oligodendrocyte differentiation
- Therapeutic timing: Critical for optimal remyelination
- Clinical trials: FGF18 completed Phase 1 [@fgf18msc]
¶ Stroke and Brain Injury
FGF promotes neural repair:
- Angiogenesis: Stimulates blood vessel formation
- Neurogenesis: FGFR1/2 in neural stem cell niches
- Synaptogenesis: Promotes dendritic spine formation
- Clinical trials: bFGF in stroke trials
FGFs mediate critical astrocyte-neuron interactions:
- Astrocyte secretion: Major source of FGF2 in brain
- Neuronal support: Paracrine signaling to neurons
- Synaptic modulation: Regulates synaptic function
- Response to injury: Increased FGF expression after injury
Astrocyte-derived extracellular vesicles:
- Carry FGFs and other neuroprotective proteins
- Therapeutic potential for neurodegeneration
| Protein |
Delivery Method |
Disease |
Status |
| FGF2 intranasal |
Intranasal |
AD |
Phase 2 |
| FGF2 intravenous |
IV delivery |
Stroke |
Phase 1/2 |
| FGF20 |
AAV vectors |
PD |
Phase 1/2 |
| FGF18 |
Intrathecal |
MS |
Phase 1 |
| FGF22 |
AAV vectors |
AD |
Preclinical |
- AAV-FGF20: Clinical trials for PD
- AAV-FGF2: Preclinical for AD
- Engineered tropism: CNS-specific promoters
- Regulated expression: Inducible systems
- FGFR-selective agonists: In development
- PD173074: Research tool compound
- Natural compounds: Phytochemicals with FGFR activity
- FGF + BDNF: Synergistic neuroprotection
- FGF + GDNF: Dopaminergic neuron protection
- With rehabilitation: Enhanced recovery
- Cell therapy: Stem cells engineered to express FGF
- Blood-brain barrier: Major obstacle
- Half-life: Short circulating half-life
- Receptor specificity: Multiple FGFRs, off-target effects
- Timing: Critical window for therapy
¶ Biomarkers and Diagnostics
- FGF2 levels: CSF and blood
- FGFR expression: Peripheral blood mononuclear cells
- pERK: Downstream activation marker
- Neurogenesis markers: DCX, Nestin with FGF levels
- FGFR PET ligands: In development
- FGF expression imaging: Reporter gene approaches
| Agent |
Target |
Mechanism |
Phase |
Disease |
| Intranasal FGF2 |
FGFR1/2 |
Neurogenesis |
Phase 2 |
AD |
| AAV-FGF20 |
FGFR1 |
Dopaminergic protection |
Phase 1/2 |
PD |
| bFGF infusion |
FGFR |
Angiogenesis |
Phase 1/2 |
Stroke |
| FGF18 |
FGFR3 |
Remyelination |
Phase 1 |
MS |
| FGF21 |
FGFR/Klotho |
Autophagy |
Preclinical |
PD |
| FGFR agonist |
FGFR |
Neuroprotection |
Preclinical |
AD |
- BDNF/TrkB: Synergistic with FGF signaling
- GDNF: Combined therapy approaches
- NGF: Interactions in cholinergic neurons
- FGF23: Acts through Klotho co-receptor
- Cognitive decline: FGF23-Klotho axis in aging
- Therapeutic implications: Klotho enhancement strategies
- FGF15/19: Neuronal lipid metabolism
- FGF21: Metabolic regulation in brain
- Therapeutic potential: Metabolic therapies